Skip to main content
Premium Trial:

Request an Annual Quote

Spanish Company Licenses Interleukin Heart Test

NEW YORK (GenomeWeb News) – Madrid-based Labec Pharma has entered a license agreement with Interleukin Genetics under which it will offer a genetic test for heart attack risk in Spain and Portugal, Interleukin Genetics said today.

Under the agreement, Labec Pharma will market the Heart Health tests, and Interleukin Genetics will process them in its lab in Waltham, Mass. Interleukin will receive royalties and milestone payments from Labec.

The companies also said that they plan to seek CE Mark certification for the test.

The test, which is sold in the US under the name Gensona, identifies variation in the IL-1 genes that are responsible for over-expression of inflammatory cytokines, which in certain individuals may be an indicator of a statistically significant risk for heart attack.

Heart disease and heart attacks are the second leading cause of death in Spain, with roughly 25,000 people dying from heart disease in the country each year, and in Portugal it accounts for around 5,000 deaths per year.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.